autoimmune bleeding disorder
Sep 18, 2018
Notizia
Argenx gets green cue in phase 2 in primary immune thrombocytopenia The Belgian biotech, Argenx has cleared phase 2 data on efgartigimod in primary immune thrombocytopenia (ITP). The results that they received, indicate at the effectiveness of the antibody Fc fragment in patients with the autoimmune bleeding disord...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
